Page 81 - 《中国药房》2026年1期

2022：2520367. dictors of tacrolimus pharmacokinetic variability：current
[ 3 ] LIN H T，CHEN L Z，WEN S Y，et al. Early diagnosis and evidences and future perspectives[J]. Expert Opin Drug
successful treatment of cytomegalovirus peritonitis in chil‐ Metab Toxicol，2020，16（9）：769-782.
dren with primary nephrotic syndrome：case series and [16] WANG J Y，HUANG L F，GAO P，et al. Diltiazem on ta‐
literature review[J]. Ren Fail，2020，42（1）：776-784. crolimus exposure and dose sparing in Chinese pediatric
[ 4 ] WEBER L T，TÖNSHOFF B，GRENDA R，et al. Clinical primary nephrotic syndrome： impact of CYP3A4，
practice recommendations for recurrence of focal and seg‐ CYP3A5，ABCB1，and SLCO1B3 polymorphisms[J]. Eur
mental glomerulosclerosis/steroid-resistant nephrotic syn‐ J Clin Pharmacol，2021，77（1）：71-77.
drome[J]. Pediatr Transplant，2021，25（3）：e13955. [17] YANG L，YANG N，YI B，et al. Population pharmacoki‐
[ 5 ] CHEN Y，QIAN S Y，CHEN Y Y，et al. KIAA0101 and netic evaluation with external validation of tacrolimus in
IL2RA were identified as core genes in hormone-resistant Chinese primary nephrotic syndrome patients[J]. Pharm
nephropathy[J]. Dis Markers，2022，2022：6545266. Res，2022，39（8）：1907-1920.
[ 6 ] DEVASENAPATHY N，CHU A，WONG M，et al. Cancer [18] HUANG L F，WANG J Y，YANG J F，et al. Impact of
risk with topical calcineurin inhibitors，pimecrolimus and sampling time variability on tacrolimus dosage regimen in
tacrolimus，for atopic dermatitis：a systematic review and pediatric primary nephrotic syndrome：single-center，pro‐
meta-analysis[J]. Lancet Child Adolesc Health，2023，7 spective，observational study[J]. Front Pharmacol，2021，
（1）：13-25. 12：726667.
[ 7 ] ECKARDT K U，KASISKE B L. Kidney disease：impro- [19] SIEDLECKI A，ANDERSON J R，JIN X，et al. RGS4 con‐
ving global outcomes[J]. Nat Rev Nephrol，2009，5（11）： trols renal blood flow and inhibits cyclosporine-mediated
650-657. nephrotoxicity[J]. Am J Transplant，2010，10（2）：231-241.
[ 8 ] VON GROOTE T C，WILLIAMS G，AU E H，et al. Im‐ [20] DE SAINT GILLES D，RABANT M，SANNIER A，et al.
munosuppressive treatment for primary membranous ne‐ Kidney biopsy findings after lung transplantation[J]. Kid‐
phropathy in adults with nephrotic syndrome[J]. Cochrane ney Int Rep，2024，9（9）：2774-2785.
Database Syst Rev，2021，11（11）：CD004293. [21] BASU B，ERDMANN S，SANDER A，et al. Long-term ef‐
[ 9 ] FU R，TAJIMA S，SUETSUGU K，et al. Biomarkers for ficacy and safety of rituximab versus tacrolimus in chil‐
individualized dosage adjustments in immunosuppressive dren with steroid-dependent nephrotic syndrome[J]. Kid‐
therapy using calcineurin inhibitors after organ transplan‐ ney Int Rep，2023，8（8）：1575-1584.
tation[J]. Acta Pharmacol Sin，2019，40（2）：151-159. [22] MO X L，CHEN X J，ZENG H S，et al. Tacrolimus in the
[10] CAVALIER E，ZIMA T，DATTA P，et al. Recommenda‐ treatment of childhood nephrotic syndrome：machine
tions for European laboratories based on the KDIGO 2024 learning detects novel biomarkers and predicts efficacy[J].
clinical practice guideline for the evaluation and manage‐ Pharmacotherapy，2023，43（1）：43-52.
ment of chronic kidney disease[J]. Clin Chem Lab Med， [23] ZHU Y，CHEN J Y，ZHANG Y，et al. Immunosuppressive
2025，63（3）：525-534. agents for frequently relapsing/steroid-dependent ne‐
[11] SHI X M，ZHONG X H，DING J. Adjuvant treatment phrotic syndrome in children：a systematic review and net‐
with Yupingfeng formula for primary nephrotic syndrome work meta-analysis[J]. Front Immunol，2024，15：1310032.
in children：a PRISMA systematic review and meta- [24] WANG L，ZHU J L，XIA M Y，et al. Comparison of ritu-
analysis of randomized controlled trials[J]. Medicine， ximab，cyclophosphamide，and tacrolimus as first steroid-
2018，97（29）：e11598. sparing agents for complicated relapsing/steroid-
[12] XU X，NIE S，ZHANG A H，et al. A new criterion for pe‐ dependent nephrotic syndrome in children：an evaluation
diatric AKI based on the reference change value of serum of the health-related quality of life[J]. Arch Med Sci，
creatinine[J]. J Am Soc Nephrol，2018，29（9）：2432-2442. 2022，18（1）：275-278.
[13] Kidney Disease：Improving Global Outcomes （KDIGO） [25] SACHDEVA S，KHAN S，DAVALOS C，et al. Manage‐
CKD Work Group. KDIGO 2024 clinical practice guide‐ ment of steroid-resistant nephrotic syndrome in children
line for the evaluation and management of chronic kidney [J]. Cureus，2021，13（11）：e19363.
disease[J]. Kidney Int，2024，105（4S）：S117-S314. [26] LARKINS N G，HAHN D，LIU I D，et al. Non-
[14] DONG J Z，FENG T，THAPA-CHHETRY B，et al. Ma‐ corticosteroid immunosuppressive medications for steroid-
chine learning model for early prediction of acute kidney sensitive nephrotic syndrome in children[J]. Cochrane Da‐
injury （AKI） in pediatric critical care[J]. Crit Care，2021， tabase Syst Rev，2024，11（11）：CD002290.
25（1）：288. （收稿日期：2025-07-16 修回日期：2025-11-28）
[15] DEGRAEVE A L，MOUDIO S，HAUFROID V，et al. Pre‐ （编辑：胡晓霖）

中国药房 2026年第37卷第1期 China Pharmacy 2026 Vol. 37 No. 1 · 71 ·